Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...
In an interview on CNBC’s Mad Money, Len Schleifer said Regeneron (REGN) currently has 40 drugs in development representing billions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback